Wednesday, October 11, 2017

Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy

Following up on the last post, Dr. Mike Lawlor sent me this in an email:

"Audentes Therapeutics officially announced the dosing of the first patient for the X-linked myotubular myopathy treatment trial that we’ve been working on over the past few years.  We’ve been very involved in the translation from dogs to humans, and will be doing the human pathology work for the trial.  Here’s a link to that press release."

Monday, October 2, 2017

Lawlor featured in video about his work in myotubular myopathy

Michael Lawlor, MD, PhD

Medical College of Wisconsin is highlighting the work of our colleague Dr. Michael Lawlor in the area of gene therapy for myotubular myopathy. Check out this wonderful 4-minute video!

Thursday, September 28, 2017

Murat Gokden releases "Neuropathologic and Neuroradiologic Correlations: A Differential Diagnostic Text and Atlas"

I got this email from Johns Hopkins AP/NP Fellow Stephen Nix:

Murat Gokden, MD

"I'm not sure if this would be something to feature on the neuropathology blog or not, but Murat Gokden just edited and released a book with Cambridge Press entitled "Neuropathologic and Neuroradiologic Correlations" (link below) focusing on combining neuropathology and neuroradiology information/findings into one resource.  I just got my copy today and the images and text look great.  Pathology contributors include Travis Danielsen, Robin Elliott, Bret Evers, Theodore Friedman, Melissa Gener, Humayun Gultekin, Eyas Hattab, Ali Hussain, Mahlon D. Johnson, Nora Laver, Beatriz Lopes, Declan McGuone, Douglas C Miller, Robert Mrak, Veena Rajaram, Fausto Rodriguez, Amyn M Rojiani, Suash Sharma, Anat O. Stemmer-Rachamimov, and Mahtab Tehrani."



Here the link to what looks like a wonderful text:
https://www.cambridge.org/core/books/neuropathologic-and-neuroradiologic-correlations/1E16A2D262637648F8E3C54B443A3706#fndtn-information





Friday, September 22, 2017

Aaron Hernandez Had Severe C.T.E. When He Died at Age 27


The New York Times reported yesterday that an autopsy report on 27-year-old Aaron Hernandez, the former New England Patriots tight end and convicted murderer, showed evidence of severe chronic traumatic encephalopathy (CTE). Hernandez committed suicide earlier this year. 

Excerpts from the article:

"Dr. Ann McKee, chief of neuropathology at the VA Boston Healthcare System and director of the CTE Center at Boston University, examined his brain and said in a statement that Mr. Hernandez had “early brain atrophy” and “large perforations in the septum pellucidum, a central membrane” of the brain. The slides also showed what she called “classic features of C.T.E. in the brain,” including deposits of tau protein in the front lobes of the brain in nerve cells around small blood vessels."

"The trauma to Mr. Hernandez’s brain raises fresh questions about the dangers of playing tackle football. This week, other researchers at Boston University published research that found that adults who began playing tackle football before they were 12 years old developed more cognitive and behavioral problems later in life than those players who started tackle football after they reached that age."

Thanks to Dr. Mark Cohen for alerting me to this article.

Tuesday, September 19, 2017

"I'm a brain scientist and I let my son play football" -- Peter Cummings, MD

Peter Cummings, MD with his son
Dr. Peter Cummings, an accomplished forensic neuropathologist, just posted an article on Yahoo Sports giving his perspective on the controversial question of whether we should let our children play football given the risk for chronic traumatic encephalopathy. Here is the link. Thanks to Dr. John Donahue of Brown University for alerting me to this article.

Monday, September 11, 2017

Guest Post from Dr. PJ Cimino: Blue discoloration of the gray matter in a patient who received methylene blue for respiratory distress prior to death

Dr. PJ Cimino, whom we profiled when he was a fellow back in November of 2013, is a now faculty member at the University of Washington. I was delighted to receive this email from him today:

"I had an autopsy case with interesting gross pathology findings, which made for some nice clinical images (below). The patient received therapeutic methylene blue in the setting of respiratory distress prior to death. The gross pathology showed striking widespread green-blue gray matter discoloration. I thought these images might be of interest to share with the general neuropatholgy community, and thought your blog might be a good platform to do so, especially since you have posted many good clinical images."




Friday, September 8, 2017

American Board of Pathology Maintenance of Certification Exam Pass Rate Dips to 97.7%!!!

The American Board of Pathology (ABP) recently published their pass rates for the Spring 2017 administration. After maintaining a 100% pass rate for the previous four administrations of the exam over two years, the Spring 2017 exam pass rate has dipped to an appalling 97.7%!

A total of 265 individuals took the exam (at $700 per examinee, the ABP brought in a paultry $185,000 from this administration). Included in this number is probably the few like me who only took the neuropathology exam, with the majority likely taking the AP/CP exam.

Bottom line: No need to worry about either your likelihood of passing the MOC exam or the financial well-being of the ABP.

Friday, August 25, 2017

I took the American Board of Pathology Neuropathology Maintenence of Certification Exam

I took the American Board of Pathology neuropathology maintenance of certification exam this week. Given that the ABP goal is virtually a 100% pass rate, I found the test more difficult than I anticipated. I suppose I shouldn't have been surprised by the level of difficulty of some of the questions, given that the ABP publishes the topics covered. But in some cases knowing the topic does not really help with preparation. For example, one topic listed is: "abnormal corticospinal tracts/pyramids". In any case, I am sure the cut-off score for passing is relatively low. Results, which only entail whether or not one has passed, will be released in October.